Dianne C.  Whitfield net worth and biography

Dianne Whitfield Biography and Net Worth

Chief Human Resources Officer of Tarsus Pharmaceuticals

Dianne brings more than 20 years of experience in human resources, including over a decade of life sciences industry management and leadership. Prior to joining Tarsus, Dianne served as Vice President and Head of Human Resources for Evolus, Inc. (NASDAQ: EOLS), where she led efforts to support the commercialization of the start-up company’s first approved product. While at Evolus, she focused on recruiting top talent, building a positive culture and fostering an effective employee experience in order to drive engagement and business results.

Prior to Evolus, Dianne held positions of increasing responsibility at Allergan (an AbbVie company), progressing to Director of Global Human Resources. Her experience there spanned a variety of human resources business partnership and leadership roles, where she supported both the Commercial and Research & Development organizations and led enterprise-wide initiatives in Global Talent Management. She has broad experience building organizations and supporting product launches in multiple therapeutic areas, including eye care, as well as expertise in developing culture and talent programs. Dianne holds a BA in psychology and social behavior from the University of California, Irvine and a Masters in social work from California State University, Long Beach.

What is Dianne C. Whitfield's net worth?

The estimated net worth of Dianne C. Whitfield is at least $1.29 million as of November 30th, 2023. Ms. Whitfield owns 26,784 shares of Tarsus Pharmaceuticals stock worth more than $1,288,043 as of March 15th. This net worth approximation does not reflect any other assets that Ms. Whitfield may own. Additionally, Ms. Whitfield receives an annual salary of $578,900.00 as Chief Human Resources Officer at Tarsus Pharmaceuticals. Learn More about Dianne C. Whitfield's net worth.

How old is Dianne C. Whitfield?

Ms. Whitfield is currently 47 years old. There are 5 older executives and no younger executives at Tarsus Pharmaceuticals. The oldest executive at Tarsus Pharmaceuticals is Mr. Jeffrey S. Farrow, CFO & Chief Strategy Officer, who is 62 years old. Learn More on Dianne C. Whitfield's age.

What is Dianne C. Whitfield's salary?

As the Chief Human Resources Officer of Tarsus Pharmaceuticals, Inc., Ms. Whitfield earns $578,900.00 per year. There are 3 executives that earn more than Ms. Whitfield. The highest earning executive at Tarsus Pharmaceuticals is Dr. Seshadri Neervannan Ph.D., Chief Operating Officer, who commands a salary of $759,200.00 per year. Learn More on Dianne C. Whitfield's salary.

How do I contact Dianne C. Whitfield?

The corporate mailing address for Ms. Whitfield and other Tarsus Pharmaceuticals executives is , , . Tarsus Pharmaceuticals can also be reached via phone at 949-409-9820 and via email at ir@tarsusrx.com. Learn More on Dianne C. Whitfield's contact information.

Has Dianne C. Whitfield been buying or selling shares of Tarsus Pharmaceuticals?

Dianne C. Whitfield has not been actively trading shares of Tarsus Pharmaceuticals over the course of the past ninety days. Most recently, Dianne C. Whitfield sold 8,355 shares of the business's stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $16.31, for a transaction totalling $136,270.05. Following the completion of the sale, the insider now directly owns 26,784 shares of the company's stock, valued at $436,847.04. Learn More on Dianne C. Whitfield's trading history.

Who are Tarsus Pharmaceuticals' active insiders?

Tarsus Pharmaceuticals' insider roster includes D. Ackermann (Director), Bobak Azamian (CEO), Andrew Goldberg (Director), Leonard Greenstein (CFO), Elizabeth Lin (Director), Aziz Mottiwala (Insider), Seshadri Neervannan (COO), Bryan Wahl (General Counsel), and Dianne Whitfield (Chief Human Resources Officer). Learn More on Tarsus Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Tarsus Pharmaceuticals?

During the last year, insiders at the sold shares 4 times. They sold a total of 24,496 shares worth more than $749,577.60. The most recent insider tranaction occured on March, 18th when insider Aziz Mottiwala sold 4,766 shares worth more than $145,839.60. Insiders at Tarsus Pharmaceuticals own 8.3% of the company. Learn More about insider trades at Tarsus Pharmaceuticals.

Information on this page was last updated on 3/18/2024.

Dianne C. Whitfield Insider Trading History at Tarsus Pharmaceuticals

See Full Table

Dianne C. Whitfield Buying and Selling Activity at Tarsus Pharmaceuticals

This chart shows Dianne C Whitfield's buying and selling at Tarsus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

Tarsus Pharmaceuticals Company Overview

Tarsus Pharmaceuticals logo
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $48.09
Low: $45.60
High: $48.23

50 Day Range

MA: $49.11
Low: $41.29
High: $56.94

2 Week Range

Now: $48.09
Low: $20.08
High: $57.28

Volume

487,715 shs

Average Volume

639,551 shs

Market Capitalization

$1.85 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05